Zacks Research Upgrades Daiichi Sankyo (OTCMKTS:DSNKY) to Hold

Daiichi Sankyo (OTCMKTS:DSNKY) was upgraded by analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued to investors on Monday, Zacks reports.

Separately, Jefferies Financial Group downgraded shares of Daiichi Sankyo from a “buy” rating to a “hold” rating in a research note on Thursday, July 30th. Two equities research analysts have rated the stock with a Hold rating, According to MarketBeat.com, the stock presently has an average rating of “Hold”.

Daiichi Sankyo Stock Performance

Shares of DSNKY stock opened at $19.00 on Monday. Daiichi Sankyo has a 12 month low of $14.98 and a 12 month high of $27.50. The company’s fifty day simple moving average is $17.67 and its 200-day simple moving average is $17.27. The firm has a market cap of $35.39 billion, a PE ratio of 22.09, a P/E/G ratio of 2.61 and a beta of -0.11. The company has a quick ratio of 1.96, a current ratio of 2.92 and a debt-to-equity ratio of 0.29.

Daiichi Sankyo (OTCMKTS:DSNKY) last released its earnings results on Friday, July 31st. The company reported $0.24 earnings per share for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01). Daiichi Sankyo had a net margin of 10.92% and a return on equity of 14.35%. The business had revenue of $3.61 billion during the quarter, compared to the consensus estimate of $3.32 billion. Daiichi Sankyo has set its FY 2026 guidance at 0.870-0.870 EPS. Equities research analysts expect that Daiichi Sankyo will post 0.97 EPS for the current fiscal year.

Daiichi Sankyo Company Profile

Daiichi Sankyo Co, Ltd. is a Japan-based pharmaceutical company focused on the research, development, manufacture and commercialization of medicines. Its primary areas of activity include oncology, cardiovascular disease, and other specialty therapeutic fields, with an emphasis on innovative treatments and technologies.

The company is particularly known for its antibody-drug conjugate (ADC) platform, which is designed to deliver potent cancer medicines directly to tumor cells. Daiichi Sankyo’s oncology portfolio includes Enhertu (trastuzumab deruxtecan), developed in collaboration with AstraZeneca, as well as other marketed and investigational ADC therapies.